NICE
NICE turns down AZ’s chronic obstructive pulmonary disease drug
February 13, 2017Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …
Alexion hits out at NICE ruling on Strensiq
February 8, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …
NICE rejects Pfizer’s first-in-class breast cancer drug
February 3, 2017Medical Communications, Sales and Marketing NICE, Pfizer, breast cancer
NICE has published draft guidelines which reject Pfizer’s Ibrance (palbociclib) based primarily on the cost of the drug but also …
New NICE ultra-rare disease proposals “not fit for purpose”, says BIA
January 16, 2017Manufacturing and Production BioIndustry Association, NICE
The BioIndustry Association (BIA) has accused new proposals put forward by the National Institute for Health and Care Excellence (NICE) …
NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment
January 13, 2017Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus
In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …
Insider interview: NICE discusses its planned ‘fast-track’ appraisal process
December 19, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, approval
Jenniffer Prescott, associate director of planning, operations and topic selection, answers questions on NICE’s recent plans for a ‘fast-track’ appraisal …
Insider interview: NICE discusses its planned ‘fast-track’ appraisal process
December 16, 2016Medical Communications, Sales and Marketing NICE
Jenniffer Prescott, associate director of planning, operations and topic selection, answers questions on NICE’s recent plans for a ‘fast-track’ appraisal …
NICE and FDA to collaborate in medtech access scheme
December 15, 2016Medical Communications, Sales and Marketing FDA, NICE
The National Institute of Health and Care Excellence (NICE) and the US Food and Drugs Administration (FDA) have announced their …
NICE approves MSD’s Keytruda for new cancer indication
December 1, 2016Medical Communications, Sales and Marketing MSD, NICE, keytruda
The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …
NICE recommends GSK’s “first-in-class” asthma drug
November 30, 2016Sales and Marketing GSK, NICE, Nucala, asthma
NICE has announced its recommendation of GSK’s “first-in-class” biologic Nucala (mepolizumab) as an extra option for the treatment of adults …
NICE recommends 4p breast cancer drug for healthy women
November 29, 2016Research and Development, Sales and Marketing NICE, anastrozole, breast cancer
NICE has published new draft guidance calling for women with a strong family history of breast cancer to be offered …
Insider interview: Roche discusses efficacy of CDF and NICE
November 25, 2016Medical Communications, Sales and Marketing CDF, NICE, Roche
Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National …
Lowered price wins NICE approval for Janssen leukaemia treatment
November 25, 2016Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica
After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
NICE u-turns on Celgene’s drug for multiple myeloma
November 24, 2016Medical Communications Celgene, NICE, imnovid
NICE has performed a U-turn on Celgene’s Imnovid (pomalidomide) based on new data and the offer of a price reduction. …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
Latest content
FibroFind appoints Lee Borthwick as CEO
